Amid scrutiny FDA hits slowdown on accelerated drug approvals
Expedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from
Read moreExpedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from
Read moreAs recently as July, Tesla Chief Executive Elon Musk said the electric-car maker did not have a problem with customer
Read moreChina’s factory activity growth slipped sharply in July as demand contracted for the first time in more than a year.
Read more